Cerbios-Pharma boosts PROVEO™ team at WORLD ADC San Diego
Press Release | Cerbios-Pharma SA
SEPTEMBER 04, 2017
Lugano, Switzerland:- Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) will be a key part of the multinational PROVEO™ Alliance presence promoting advanced integrated solutions at September’s ADC World conference in San Diego.
PROVEO™ and Cerbios are returning to ADC World following a highly successful showing at ADC World Berlin in the spring.
Integrated manufacturing solution
In San Diego, a team from Cerbios, including CEO, Dr. Gabriel Haering, CCO Denis Angioletti and Business Development leaders Simone Sala and Matteo Piazza will be present on the PROVEO™ stand at the co-located trade show, presenting its offer as a one stop shop for ADC solutions.
“We will be reaching out to pharma companies, bio-ventures and start-ups involved in ADC, and oncology,” said Dr. Gabriel Haering.
“We will be able to show that Cerbios expertise in the payload and conjugation aspects of ADC technology plays a key role in the overall Proveo ‘one stop shop’ proposition,” he explained.
Payload and conjugation expertise
“We Cerbios team members will be able to provide detail on the company’s GMP capabilities to handle toxic payload, as well as its focus on conjugation process development and scale up,” added COO Denis Angioletti.
“During our 40th Anniversary Year, we have been deepening our core expertise in HPAIs and Recombinants and extending our CMO offers to include ADC manufacturing capabilities enhanced by new synergies with partners in Denmark and Germany as part of the PROVEO™ Alliance,” said Mr. Angioletti.
Cerbios-Pharma SA is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners worldwide. Cerbios specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of fine chemicals and biologicals.
Cerbios Chemical Division offers exclusive, third party manufacturing services for HPAIs while Biological Division produces monoclonal antibodies, recombinant proteins and pharma probiotics.
Cerbios provides full CMC support to its worldwide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with CMC Biologics of Denmark, together with Germany’s Oncotec and IDT Biologika. PROVEO™ can offer a one-stop shop service from substance development through to full finish.
About ADC World 2017
The ADC World conference is the industry’s longest standing and most comprehensive event devoted to Antibody Drug Conjugate technology and solutions.
The event aims to generate new insights and connections to promote development of more clinically impactful ADCs.
The 8th conference, ADC World 2017, will be a three-day event opening September 20 at the Sheraton hotel at San Diego Marina.
The 2017 conference will feature more than 90 industry expert speakers, discussing a wide range of topics including identifying novel tumor associated antigens, cleaner targets, optimized linker-drug chemistries, translatable animal models and CMC improvements.
The event is organized by Hanson Wade with more information at: http://worldadc-usa.com.
Simone Sala, BD Manager; Cerbios-Pharma SA
Tel: +41 91 985 6311